Successful cancer chemotherapy ideally exploits defined metabolic differences between malignant and normal cells. Unfortunately, no clean-cut enzymatic differences have been discovered. In 1977, however, Toohey (1) described four mouse tumors that were deficient in the. polyamine-related enzyme 5'-methylthioadenosine phosphorylase (MeSAdo phosphorylase). A preliminary survey of established human leukemic cell lines also disclosed that 5 of 13 were deficient in MeSAdo phosphorylase. The enzyme-negative cell lines excreted large amounts of 5'-methylthioadenosine (MeSAdo) into the culture medium (2).
Successful cancer chemotherapy ideally exploits defined metabolic differences between malignant and normal cells. Unfortunately, no clean-cut enzymatic differences have been discovered. In 1977, however, Toohey (1) described four mouse tumors that were deficient in the. polyamine-related enzyme 5 '-methylthioadenosine phosphorylase (MeSAdo phosphorylase). A preliminary survey of established human leukemic cell lines also disclosed that 5 of 13 were deficient in MeSAdo phosphorylase. The enzyme-negative cell lines excreted large amounts of 5'-methylthioadenosine (MeSAdo) into the culture medium (2) .
In mammalian cells, MeSAdo is produced during synthesis of the aliphatic polyamines spermidine and spermine from decarboxylated S-adenosylmethionine (3) (Fig. 1) . MeSAdo does not accumulate in normal tissues (4) but is cleaved rapidly to adenine and 5-methylthioribose-1-phosphate by MeSAdo phosphorylase (5), which is abundant in all organs of the rat examined (6) . The adenine presumably is reconverted to purine nucleotides via adenine phosphoribosyltransferase (EC 2.4.2.7). The loss of MeSAdo phosphorylase, by decreasing adenine formation, would be expected to interfere with this salvage pathway.
The purposes of the present experiments were (i) to determine the distribution of MeSAdo phosphorylase levels and the incidence of enzyme deficiency among a large number of human cell lines derived from normal and malignant tissues of diverse origin, (ii) to develop a method for assessment of the phosphorylase in individual cells from normal and cancerous tissue specimens, and (iii) to devise a chemotherapeutic strategy that could selectively kill enzyme-deficient cells. The results show that MeSAdo phosphorylase was undetectable in 7 out of 31 (23%) cell lines derived from leukemia, malignant melanoma, and breast cancer, but in none of 16 (8) , HPB-ALL (9), NALL-1 (10), and Reh (11) , all derived from ALL; TALL-i (12), derived from lymphosarcoma; U937 (13) , derived from histiocytic leukemia; and Daudi, derived from African Burkitt's lymphoma (14) . MOLT 4 (15) , derived from ALL, came from J. Minowada (Roswell Park Memorial Institute, Buffalo, NY). Raji (16) , derived from African Burkitt's lymphoma, K562 (17) , from the pleural effusion of a patient with chronic myelocytic leukemia in blast crisis, and BJA-B, from Burkitt's lymphoma (18) (19) and Hs602T (19) , derived from lymphoma; Hs324T (19) , from reticulum cell sarcoma; Hs445T (20) , from Hodgkin's disease; Hs427T (19) , from lymphosarcoma; BT20 (21), MDA-MB-157 (22) , (23) , and 734B (24) , all from breast cancer; A375 (25) , Hs294T (26, 27) , Hs695T (27) , Hs852T (27) , Hs936T/Cl (28) , Hs939T (29) , and Hs944T, all from melanoma; Hs578T (30) , from breast carcinosarcoma; and HBL-100 (31), § from a milk sample. Among 16 cell lines of nonmalignant origin, WI-L2 (32), derived from a spleen sample of a patient with spherocytosis, came from R.
Abbreviations: MeSAdo, 5'-methylthioadenosine; ClAdo, 5'-chloroadenosine; ALL, acute lymphocytic leukemia; AdoMet, S-adenosylmethionine. * 0.4 MuCi in a total volume of 100 Al. The reaction was initiated by addition of radioactive substrate, and the mixture was incubated at 370C for 10-60 min. The reaction was then terminated by immersion in a boiling water bath for 2 min. Insoluble material was sedimented at 2500 X g for 10 min, and 10 ,l of the supernatants was applied to polyethyleneimine-cellulose sheets (no. 5504, Merck, Darmstadt, Federal Republic of Germany). Radioactive adenine was separated from ClAdo in 1 M ammonium acetate developed in the presence of unlabeled standards. Adenine was visualized under ultraviolet light and cut out, and radioactivity was measured in a liquid scintillation spectrometer at an efficiency of 23%. The formation of product was linear with respect to both protein concentration and time for each of the values reported.
Autoradiography. For measurement of MeSAdo phosphorylase by autoradiography, horse serum, which lacks the enzyme, was substituted for fetal calf serum, which had abundant enzyme activity (0.59 nmol/min per ml). Monolayer (Fig. 2) . Considering the sensitivity of the radioenzyme assay, the activity of each enzyme-negative cell line was at most 0.001 nmol/min per mg of protein (i.e., <1% of the lowest activity of enzyme-positive cell lines). Among .g., Fig. 3C ). Thus, there was no evidence for metabolic cooperation between enzyme-positive and enzyme-negative cells under these conditions. Cells from two bone marrow specimens and one peripheral blood specimen from patients with ALL, and cells from an adenocarcinomatous pleural effusion of unknown origin were also incubated with Cl[2-3H]Ado. In each case, more than 70% of the nucleated cells incorportated radioactivity into nucleic acid (Fig. 4) .
In other experiments, human B lymphoblastoid cells defi- (1981) 1223 prevented by addition of exogenous adenine to the culture medium. Under these conditions, the conversion of adenine to nucleotides by adenine phosphoribosyltransferase provided a sufficient source of purines for nucleic acid synthesis. In the MeSAdo phosphorylase-positive cells incubated with methotrexate/pyrimidine or with azaserine, addition of MeSAdo to the culture medium also provided a sufficient source of purines for growth. Because the enzyme-deficient cells were unable to use the nucleoside, they failed to survive under such selective conditions.
By autoradiography, we were unable to demonstrate any transfer of the adenine moiety of MeSAdo from enzyme-positive to enzyme-negative cells cultured together. Thus, most of the adenine produced by MeSAdo cleavage was converted to adenine nucleotides rather than excreted. The selective killing of MeSAdo phosphorylase-deficient cells in a mixed cellular population would appear to be feasible.
In an initial screening of four human tumor specimens, all were MeSAdo phosphorylase positive. More extensive experiments are required to determine the true incidence of enzyme deficiency among human malignant neoplasms in vivo, both before and after chemotherapy. The demonstrated chemotherapeutic efficacy of methotrexate is limited by its toxicity to normal, rapidly proliferating tissues such as intestinal mucosa and bone marrow. Attempts have been made to rescue normal cells by infusing thymidine (41, 42) . In a patient with malignant tumor deficient in the enzyme, the infusion of MeSAdo alone or in combination with thymidine might protect the normal tissues without affecting the toxicity of methotrexate for the malignant cells. In this way, a naturally occurring enzyme deficiency among human malignancies could be exploited successfully.
